A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

NCT03311334 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision to terminate development of the program.

Conditions

Renal Cell Carcinoma (RCC)
Urothelial Carcinoma
Primary Peritoneal Cancer
Platinum-resistant Ovarian Cancer (PROC)
Serous Epithelial Ovarian Cancer
Fallopian Tube Cancer

Interventions

DRUG: DSP-7888 Dosing Emulsion
DRUG: Nivolumab
DRUG: Pembrolizumab

Sponsor

Sumitomo Pharma America, Inc.